SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys agreement to supply engines, license propulsion technology and provide engineering support for AST SpaceMobiles planned Blacklift rocket is driving attention, with traders viewing it as major contract validation and a boost to Fireflys backlog. The rally has also drawn caution over share-based payment, execution risks for the rocket program and volatility around earnings.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.17847452 USD and is down -3.32 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,362,443,159.56 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp selloff and underperformance are driving debate, with many traders blaming the midterm results and perceived uncertainty around the CLARITY Act, while others point to broader crypto weakness and concerns about XRPs supply and utility. Dip buyers and long-term holders are countering the bearish sentiment by accumulating, but the discussion remains divided.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon shares are drawing attention after a sharp selloff despite traders describing the latest quarterly results as a beat and noting the company maintained its guidance. The community is split between calling the drop an overreaction and buying for a bounce, and pointing to persistent underperformance and debt concerns; options chatter is also divided between calls and puts.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA for sonelokimab in hidradenitis suppurativa and the expected FDA filing-acceptance and review-timeline decision are the main focus. Traders debate whether acceptance or priority review could improve sentiment, while skeptics point to rejection risk and concerns about the company commercializing alone and needing further financing.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic stake is drawing attention as the AI companys IPO filing and private-market valuation fuel speculation that Zoom offers indirect exposure to the listing. Bulls see the stake and Zooms cash flow as overlooked value, while skeptics argue the investment is uncertain and the core business faces slow growth and competition.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humanas quarterly results and higher full-year outlook are driving attention, with traders welcoming the earnings beat and guidance increase. Some caution that the adjusted outlook rose only modestly, the GAAP increase includes a noncash accounting reversal, and elevated medical costs remain a concern.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,953,127.30655279. The last known price of Zcash is 1,329.33960893 USD and is up 1.05 over the last 24 hours. It is currently trading on 668 active market(s) with $1,328,780,662.72 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rally and outperformance versus Bitcoin are drawing attention, with traders frequently pointing to the NU7 network upgrade and renewed interest in privacy-focused crypto as catalysts. Bullish calls for further gains coexist with skepticism about resistance levels and expectations of a pullback.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Repeated Schwab and thinkorswim outages, including login and order-processing problems and inaccurate platform data, are driving complaints from traders who say disruptions interfered with trades. Some report access restored, while others remain frustrated and are considering moving their accounts to competing brokerages.

Official Melania Meme (MELANIA) is a cryptocurrency and operates on the Solana platform. Official Melania Meme has a current supply of 999,995,428.757519 with 999,995,428.757515 in circulation. The last known price of Official Melania Meme is 0.06224781 USD and is up 1.19 over the last 24 hours. It is currently trading on 310 active market(s) with $4,914,204.93 traded over the last 24 hours. More information can be found at https://melaniameme.com/.

Melania Trump

MELANIA is drawing attention as traders debate its steep decline and whether the politically branded meme coin has any lasting value; many call it a failed cash grab and point to heavy losses, while a smaller group speculates about a rebound or short-term pump.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

A steep post-IPO decline is driving debate, with traders pointing to Piper Sandlers bearish coverage and weakness across nuclear stocks, while some also blame lockup-related selling. Bulls cite Amazons backing and X-energys reactor projects for long-term potential, but others worry commercialization is years away and near-term news may not offset the selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational flexibility. The transaction...

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026.Webcast and Conference Call DetailsInvestors may access a live...

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this weeks American Heart Association Scientific Sessions in Chicago. AHA 2026 Oral Presentations Date & Time: Saturday, November 7, 3:15 4:30 pm CT Session Title: FS.05: Featured Science Session...

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS to reduce extremely high levels of...

Top 3 Health Care Stocks That Could Blast Off In October

Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.read more...

Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know

Equity

In the Phase 1/2a trial, patients receiving Arrowhead’s drug saw an average 73% reduction in tau protein levels in cerebrospinal fluid after 105 days, with a maximum reduction of 85%.


Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimers disease and other tauopathies. These results...

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowheads upcoming supplemental new drug application (sNDA) for...

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimers Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowheads central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>The company tested three doses of ARO-MAPT: 2.1 mg/kg, 6.4 mg/kg, and 12.8 mg/kg.</li><li>The drug was generally well tolerated, with no serious treatment-emergent adverse events or deaths reported.</li><li>Arrowhead is continuing enrollment of patients with early Alzheimer’s disease, with data expected in 2027.</li></ul>Arrowhead Pharmaceuticals (ARWR) was on investors’ radar on Wednesday, after the biotech firm reported strong early results for its experimental Alzheimer’s disease treatment, ARO-MAPT, which significantly reduced levels of a protein linked to the disease.<a class="mention" data-mention="$ARWR" data-symbol-id="ARWR" href="https://stocktwits.com/symbol/ARWR" target="_blank">ARWR shares</a> jumped more than 4% after the update but pared some of the gains. It traded about 2% higher, as of this writing.<h2 class="st-heading-2">What Did The Trial Show?</h2>ARO-MAPT is being developed to reduce tau production, a protein associated with Alzheimer’s disease and other neurological disorders. In the Phase 1/2a trial, patients receiving the drug saw an average 73% reduction in tau protein levels in cerebrospinal fluid (CSF) after 105 days, with a maximum reduction of 85%.The company tested three doses of ARO-MAPT – 2.1 mg/kg, 6.4 mg/kg, and 12.8 mg/kg. Arrowhead said the tests support the potential for dosing once every three months.The drug was generally well tolerated, with mostly mild side effects and no serious treatment-emergent adverse events or deaths reported. Arrowhead is continuing enrollment of patients with early Alzheimer’s disease, with data expected in 2027. The company has also begun regulatory discussions for the trial.<h2 class="st-heading-2">ARWR’s Pipeline Includes Cardiovascular, Liver Treatments</h2>Beyond Alzheimer’s, Arrowhead is also developing treatments for cardiovascular, liver, metabolic, and neurological diseases. Its portfolio includes Plozasiran, marketed as Redemplo for a rare triglyceride disorder, and experimental drugs such as Zodasiran for cholesterol-related disorders and Fazirsiran for a rare genetic liver disease.Arrowhead reported around $1.57 billion in total cash resources, including marketable securities, as of June 30, 2026.<h2 class="st-heading-2">What Retail Thinks About ARWR</h2>Retail sentiment surrounding ARWR on Stocktwits turned ‘neutral’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.One user called the data ‘extremely strong’ and said it beat the company’s own expectations.<stembedurl>https://stocktwits.com/Wolfman5960/message/666446488</stembedurl>Another user said the update should have driven the stock up $65 “at a minimum.” The stock is currently trading at about $60.<stembedurl>https://stocktwits.com/CrispDry/message/666462513</stembedurl>ARWR shares are down around 13% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/lqda-stock-rockets-btig-calls-united-therapeutics-settlement-better-than-best-case-scenario/cZxfqAqRBqd">&nbsp;LQDA Stock Rockets 40% Today – BTIG Calls United Therapeutics Settlement ‘Better Than Best-Case Scenario’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The company tested three doses of ARO-MAPT: 2.1 mg/kg, 6.4 mg/kg, and 12.8 mg/kg.

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$58.16
Prev Close	$57.46
Open	$58.21
Dividend Yield	0.00%
50-Day Moving Average	$66.91
Beta	1.70
Avg. Volume	1.73M
PE Ratio	-25.93

52-Week High	$95.49
52-Week Low	$37.06
Market Capitalization	$8.12B
EPS (Annual)	-$0.0122
Price to Book	17.63
Revenue Per Employee	$1.17M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARWR Fundamentals